Jul 2026· Journal of Immunology· Vol 215· 0 citations
TL;DR
Loss-of-function analysis of ZFC3H1 and DYNLT3 in A375 melanoma cells provides new insight into their potential roles in tumor cell growth and regulation, which may help define RNA-processing and transport mechanisms that support melanoma progression and identify novel targets for therapeutic intervention.
Abstract
Melanoma progression is driven by transcriptional and cytoskeletal regulators that influence cell proliferation, migration, and immune evasion. ZFC3H1, a zinc finger RNA-binding protein involved in nuclear RNA decay, and DYNLT3, a dynein light-chain component implicated in intracellular transport and signaling, are both aberrantly expressed in melanoma according to public transcriptomic datasets. This study investigates the functional roles of ZFC3H1 and DYNLT3 in A375 melanoma cells to determine whether their dysregulation contributes to tumor growth or survival.
Differential expression analysis of RNA-seq data from melanoma and normal skin samples identified ZFC3H1 and DYNLT3 as upregulated genes. CRISPR-Cas9 knockouts were generated in A375 cells to assess loss-of-function effects. RNA extraction and cDNA synthesis confirmed knockout efficiency by qPCR. Cell viability and proliferation were evaluated using trypan blue exclusion and standard colorimetric assays. Ongoing assays are examining changes in morphology and expression of stress-response genes following knockout.
Preliminary results confirmed robust expression of ZFC3H1 and DYNLT3 in wild-type A375 cells and successful CRISPR knockout in target lines. Early viability assays suggest reduced proliferation in DYNLT3-deficient cells, while ZFC3H1 knockout shows altered morphology consistent with cytoskeletal disruption. Additional analyses are underway to quantify transcriptional and phenotypic effects relative to control cells.
Loss-of-function analysis of ZFC3H1 and DYNLT3 in A375 melanoma cells provides new insight into their potential roles in tumor cell growth and regulation. These findings may help define RNA-processing and transport mechanisms that support melanoma progression and identify novel targets for therapeutic intervention.
n/a
Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
Both in vitro assays and in vivo models confirmed that silencing ZNF695 dramatically suppresses CRC cell proliferation, migration, and invasion, while concurrently impeding tumor progression.
Xiaozhun Tang, H. Ke, Ying Huang· Molecular Carcinogenesis· 0 citations
Findings indicate that ZFP36L1 plays a context-dependent role in regulating genomic stability and cellular responses to genotoxic stress, highlighting its potential as a biomarker and therapeutic target in triple-negative breast cancer.
Hope H. G. Gandu, Purity T. Y. Gandu, Efe Okorare et al.· bioRxiv· 0 citations
A specific mechanism whereby HOXC9 transcriptionally activates NRP1 is elucidated, thereby contributing to CRC malignant development and immune evasion and elucidate a specific mechanism whereby NRP1 overexpression could reverse CRC progression inhibition and immune function enhancement caused by HOXC9 downregulation.
Xiaofeng Qiu, Sheng Hu, Bingling Liao et al.· Zeitschrift für Induktive Ab...· 0 citations
It is demonstrated that NOP2 promotes LUAD progression by regulating FKBP4 expression, potentially through m5C methylation, thereby highlighting the NOP2/FKBP4 axis as a potential therapeutic target.
Findings highlight a HuR-SerpinB9 axis that regulates T-cell senescence and persistence, offering a potential therapeutic target in cancer and autoimmune diseases.
P. Chakraborty, Mrinmoyee Majumder, W. Wofford et al.· Journal of Immunology· 0 citations
Findings identify NTMT1 as a candidate regulatory node associated with MYC activation and downstream HLA-A suppression, warranting further mechanistic and in-vivo investigation, and highlighting NTMT1 as a promising candidate for future therapeutic investigation.
Jin-Ling Zhang, Chen Chen, Huibin Song et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.